論文

査読有り 筆頭著者
2013年5月

Cost-effectiveness analysis of omalizumab for the treatment of severe asthma in Japan and the value of responder prediction methods based on a multinational trial

Value in Health Regional Issues
  • Toshitaka Morishima
  • ,
  • Hiroshi Ikai
  • ,
  • Yuichi Imanaka

2
1
開始ページ
29
終了ページ
36
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.vhri.2013.01.007

Objectives: Omalizumab improves health outcomes for patients with severe asthma. The purpose of this study was to conduct a cost-utility analysis of omalizumab from a societal perspective by using the results from a randomized controlled trial in Japan, and explore the efficient use of omalizumab. Methods: We developed a Markov model to compare omalizumab add-on therapy with standard therapy. Patients transitioned between symptom-free, day-to-day, and exacerbation states. Our model had a lifetime horizon in which 5-year omalizumab add-on therapy was followed by standard therapy. Preference-based utilities were extracted from another study. We estimated the expected value of perfect information for patients' response to omalizumab. Results: In the base case, incremental cost-effectiveness ratio (ICER) for omalizumab add-on therapy was US $755,200 (95% credible interval [CI] $614,200-$1,298,500) per quality-adjusted life-year gained, compared with standard therapy alone. One-way sensitivity analyses indicated that the results were sensitive to asthma-related mortality, exacerbation risk, and omalizumab cost. The ICER for a responder subgroup was 22% lower than that in the base case. Individual and population expected value of perfect informations for the response were $4100 (95% CI $2500-$6000) and $28 million (95% CI $17 million-$42 million) per year, respectively. Conclusions: With a willingness-to-pay of $45,000 per quality-adjusted life-year, omalizumab was not cost-effective in Japan. Confining omalizumab therapy to previously predicted responders, however, may be a reasonable strategy to reduce the ICER, as the cost-effectiveness was observed to improve for these patients. Further studies should be conducted to explore responder prediction methods. Decreasing the price of omalizumab would improve cost-effectiveness. © 2013 International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

リンク情報
DOI
https://doi.org/10.1016/j.vhri.2013.01.007
URL
https://www.sciencedirect.com/science/article/pii/S2212109913000083
ID情報
  • DOI : 10.1016/j.vhri.2013.01.007
  • ISSN : 2212-1099
  • SCOPUS ID : 84877123278

エクスポート
BibTeX RIS